RARE PHOTOS: Here s what to expect from charles river laboratories next earnings report | Rare Historical Photos

With a market cap of $7.7 billion, Charles River Laboratories International, Inc. (CRL) is a global, full-service contract research organization that supports the early stages of drug discovery and development. Through its three segments: Research Models and Services (RMS); Discovery and Safety Assessment (DSA); and Manufacturing Solutions, the company provides essential products and services to pharmaceutical, biotechnology, academic, and government clients worldwide.

The Wilmington, Massachusetts-based company is slated to announce its fiscal Q2 2025 earnings results before the market opens on Wednesday, Aug. 6. Ahead of the event, analysts expect CRL to report an adjusted EPS of $2.50, down 10.7% from $2.80 in the year-ago quarter. However, the company has surpassed Wall Street's bottom-line estimates in the past four quarterly reports.